All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Sleeping Beauty (SB) transposon, a type of nonviral integrative vectors, provides an alternative to modify primary T cells. Creative biolabs has developed SB transposon CAR vector pSBCAR1 PSCA (2B3) h(28BBζ), which is constructed for the engineering of T cells to target human PSCA. The T cells are genetically modified through transduction with a nonviral vector expressing scFv of anti-PSCA antibody linked to a CD28 transmembrane domain/ endodomain and CD137 (4-1BB), CD3-zeta signaling domains. And the vector product was designed for the treatment of Prostate cancer.
CAR Construction : Fig.1 Competition ELISA binding assay against recombinant PSCA. All measurements were performed in triplicate. Leyton, J. V., Olafsen, T., Lepin, E. J., Hahm, S., Bauer, K. B., Reiter, R. E., & Wu, A. M. (2008). Humanized radioiodinated minibody for imaging of prostate stem cell antigen–expressing tumors. Clinical Cancer Research, 14(22), 7488-7496. |
CAR Construction : Fig.2 Flow cytometry a) LNCaP and c) LNCaP-PSCA cells incubated with secondary anti-human (Fc specific) PE-F(ab’)2 only or b) LNCaP or d) LNCAP-PSCA cells incubated with purified 2B3 minibody (0.1 μg/μl). All measurements were performed in triplicate. Leyton, J. V., Olafsen, T., Lepin, E. J., Hahm, S., Bauer, K. B., Reiter, R. E., & Wu, A. M. (2008). Humanized radioiodinated minibody for imaging of prostate stem cell antigen–expressing tumors. Clinical Cancer Research, 14(22), 7488-7496. |
CAR Construction : Fig.3 Flow cytometry analysis comparing binding of Cy5-cDb to 22Rv1 cells that over express PSCA (left) and the parental line (right) that expresses very low level of PSCA. Strong binding of Cy5-cDb to PSCA (orange line) was evident compared to the positive control. Sonn, G. A., Behesnilian, A. S., Jiang, Z. K., Zettlitz, K. A., Lepin, E. J., Bentolila, L. A., ... & Reiter, R. E. (2016). Fluorescent Image–Guided Surgery with an Anti-Prostate Stem Cell Antigen (PSCA) Diabody Enables Targeted Resection of Mouse Prostate Cancer Xenografts in Real TimeFluorescent Image–Guided Surgery with an Anti-PSCA Diabody. Clinical Cancer Research, 22(6), 1403-1412. |
CAR Construction : Fig.4 Quartz crystal microbalance (QCM) measurements of the interaction between mock labeled cDb or Cy5-cDb and recombinant PSCA. Mock-treated cDb had an apparent affinity of 1.96 nM and Cy5-cDb 0.42 nM, both in the low nanomolar range Sonn, G. A., Behesnilian, A. S., Jiang, Z. K., Zettlitz, K. A., Lepin, E. J., Bentolila, L. A., ... & Reiter, R. E. (2016). Fluorescent Image–Guided Surgery with an Anti-Prostate Stem Cell Antigen (PSCA) Diabody Enables Targeted Resection of Mouse Prostate Cancer Xenografts in Real TimeFluorescent Image–Guided Surgery with an Anti-PSCA Diabody. Clinical Cancer Research, 22(6), 1403-1412. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-PSCA (2B3) h(CD28-41BB-CD3ζ) CAR, pSBCAR1 (CAR-SB-02LX055). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION